# About Wolverine Research: An Editorial Digest of the BPC-157 TB-500 Literature

> Wolverine Research is an independent editorial project summarizing the peer-reviewed literature on the BPC-157 TB-500 blend. Not a clinic, not a vendor, not a prescription service — an evidence terminal.

What this terminal is, what it is not, and how it reads the BPC-157 TB-500 record.

## What this site is

Wolverine Research is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 blend. We read each constituent against its own studies and post the result as a position — confirmed where the literature confirms, flagged as a gap where the combination has never been tested.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The "terminal" framing is a reading device — a way to post directional evidence plainly — not a trading venue, and nothing here is offered for sale or supply.

## What the name means

"Wolverine" is the research-community name for the BPC-157 + TB-500 pairing, and "Research" is the position this publisher occupies relative to that literature: a reader and summarizer of it, not a participant in its supply. The name is editorial framing, not a claim about services. We do not run a pharmacy, a telehealth practice, or a clinical service, and we do not facilitate access to either peptide.

This distinction matters because both constituents are unapproved and prohibited in sport. A site that documents the evidence is not the same as a site that supplies the compound, and we are firmly the former. Where the published record and online consensus disagree, we follow the published record and cite it.

## How we source and cite

Every quantitative claim on this site resolves to a numbered citation on the [study references](/references) page — PubMed-indexed studies for the science, and FDA pages and the WADA Prohibited List for the regulatory status. We separate confirmed constituent findings from the blend-level gap, and we flag the recurring "TB-500"-versus-full-length-Thymosin-Beta-4 conflation wherever it touches a human-data claim [4][7].

For the human dataset specifically, see the [BPC-157 TB-500 clinical evidence](/clinical-evidence) page; for the regulatory picture, the [Wolverine legal status](/legal-status) page; and for the common questions, the [frequently asked questions](/faq).

---

A two-position evidence board for the BPC-157 TB-500 blend — each constituent finding posted up where the studies confirm it and down where the combination row stays empty, the FDA 503A and WADA status read off first, and nothing here listed, priced, or for sale.